Pharmaceuticals company Ami Organics announced Q1FY25 results: Revenue from operations for Q1FY25 grew by 14.9% YoY to Rs 1,767 million The gross margin for the quarter was at 42.1%. EBITDA for the quarter came at Rs 295 million down 13.2% YoY compared to Rs 340 million in Q1FY24. EBITDA margin for the quarter was at 16.7% as compared to 22.1% in Q1FY24. EBITDA margins contracted due to lower gross margins coupled with higher employee expenses led by annual increments as well as new hiring for Ankleshwar plant. PAT for the quarter was Rs 147 million. PAT margin for the quarter was 8.3%. PAT margins were impacted due to higher finance cost as well as higher depreciation cost. Commenting on results, Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am pleased to report that we continue to successfully navigate the challenging industry landscape, achieving strong revenue of ?176 crore, which represents a 14.9% year-over-year growth. This growth was primarily driven by our core pharmaceutical business, while the specialty chemicals segment saw a modest 10% increase. During the quarter, we also successfully completed the Good Manufacturing Practices (GMP) inspection by the Pharmaceutical and Medical Devices Agency (PMDA), Japan, with no critical or major observations. To our knowledge, we may be the only company in India to have successfully passed both USFDA and PMDA inspections in the advanced pharmaceutical intermediate sector. Historically, Q1 is always lowest quarter in terms of revenue each financial year since inception, and we typically see sequential growth from Q1 to Q4. I anticipate similar strong sequential growth in the coming quarters. Looking at our current order book, I am confident that we will comfortably meet our 25% growth guidance for the year.” Result PDF